fencamfamine
Small moleculeexperimental
Fencamfamin (INN), also known as fencamfamine or by the brand names Glucoenergan and Reactivan, is a stimulant which was developed by Merck in the 1960s. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 25, 2021 (NCT04638803)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CCNC1C2CCC(C2)C1c1ccccc1- Mol. weight
- 215.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFencamfamin ↗
- ChEMBLCHEMBL7010 ↗
Also known as
- fencamfamin
- fencamfamin
- fencamfamine
- fencamfamine
- fencamfamine
- fencamfamine hcl
- fencamfamine hydrochloride
- fencamfamine hydrochloride
- fencamfamine hydrochloride
- fencamfamine hydrochloride
- fencamfamine hydrochloride
- fencamfaminum
- phencamphamine
- reactivan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04638803 | Early Phase 1 (Phase 1) | Feb 25, 2021 | Hawaii Pacific Health, Praxis Biologics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hawaii Pacific Health | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Praxis Biologics | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1